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Abstract: 3D printing, as one of the most rapidly-evolving fabrication technologies, has released
a cascade of innovation in the last two decades. In the pharmaceutical field, the integration of 3D
printing technology has offered unique advantages, especially at the micro-scale. When printed at a
micro-scale, materials and devices can provide nuanced solutions to controlled release, minimally
invasive delivery, high-precision targeting, biomimetic models for drug discovery and development,
and future opportunities for personalized medicine. This review aims to cover the recent advances in
this area. First, the 3D printing techniques are introduced with respect to the technical parameters
and features that are uniquely related to each stage of pharmaceutical development. Then specific
micro-sized pharmaceutical applications of 3D printing are summarized and grouped according to
the provided benefits. Both advantages and challenges are discussed for each application. We believe
that these technologies provide compelling future solutions for modern medicine, while challenges
remain for scale-up and regulatory approval.
Keywords: additive manufacturing; 3D printing; drug delivery; micromedicine; drug development;
micro-swimmer; micro-implant; oral dosages; microneedle; high-precision targeting; controlled
release; geometry; resolution; feature size; personalized medicine; release profile; vascularization
1. Introduction
Pharmaceutical development is commonly considered to proceed in three main stages: drug
discovery, drug development, and drug delivery [1]. In drug discovery, a suitable target is first
identified. Afterwards, a library of compounds is screened for activity with the biological target,
from which an active compound is selected. In drug development, the active compound is then tested
in various settings, including in vitro models, in vivo animal studies, and clinical trials. During these
regulatory phases of intense development and testing, the exact dosing and delivery methods are
optimized. Drug delivery is comprised of precise delivery of the active pharmaceutical compound and
encompasses possibilities from oral dosages to drug-eluting micro-implants.
There are challenges which currently face each phase of pharmaceutical development. Drug
development is a long, costly process. Typically, a new pharmaceutical entity will take over a decade
to enter the market, requiring upwards of one billion dollars [2]. However, many drugs fail in later
stages of clinical trials [3], as in vitro and animal models fail to fully predict drug reaction in humans.
Animal models often produce data that are limited in their ability to translate to humans [4]. To this
end, a heavy focus of drug development research seeks more realistic and effective in vitro models.
Manufacturing better models for drug development proves to be challenging because the in vivo
response is highly nuanced [5]. A key feature of human biological systems is exquisite spatial patterning
and organization, down to the micron range It has long been known that cell response, morphology,
chemotaxis, messaging, and differentiation depend on the micro-scale environmental conditions. Thus,
in vitro models seek to faithfully recapitulate critical features of in vivo as closely as possible [6].
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The goal of pharmaceutical drug delivery is similarly complex: the ideal drug should be highly
specific in reaching and affecting its intended target, while minimizing side effects [7]. Many compounds
display inhibitory or therapeutic effects at some minimum concentration, but increase in toxicity and
side effects with increased dose, having some functional therapeutic window. Some drugs may have
narrow therapeutic windows [8], need to be tissue-specific [9], or are specific to certain patients’ genetics.
Individual biological systems are incredibly sensitive to location, dose, and timing of medication.
Because these effects are sophisticated, medicine tailored to an individual is an attractive target for the
industry [9].
However, today’s market has a limited possibility to produce personalized medicines [10].
For example, in the case of oral delivery, conventional batch methods cannot feasibly make every
dose size. Splitting doses to overcome this is associated with dose variation, and it compromises dose
coatings [11]. Additionally, current manufacturing cannot make different shaped tablets [10]. Inflexible
dosage regimes highlight a need in the pharmaceutical industry that cannot be met through current
manufacturing methods. Thus, innovative solutions are necessary.
This review aims to cover recent advances in additive manufacturing with regards to micro-sized
biomedical applications, and the potential solutions they provide to these stated challenges in drug
delivery and development. The purpose of this article is to show that the integration of 3D printing
technology has unique advantages. At a micro-scale, 3D-printed materials can provide nuanced
solutions to controlled release, minimally invasive delivery, high-precision targeting, biomimetic
models for drug discovery and development, and future opportunities for personalized medicine.
Specific micro-sized pharmaceutical applications of 3D printing are summarized and grouped according
to the provided benefits.
2. Additive Manufacturing: Methods and Resolution
3D printing, more formally known as additive manufacturing, is rapidly becoming one of the
most well-known and innovative technologies of the 21st century. Additive manufacturing is a
number of manufacturing techniques in which material is selectively placed in a layer-by-layer fashion
(Figure 1), including material extrusion, material jetting, binder jetting, selective laser sintering, and vat
polymerization. Each of these techniques is currently applied in the pharmaceutical field, and thus are
presented here [12–35].
2.1. Material Extrusion
Material extrusion is the least costly and most common type of 3D printing [36]. There are
two major categories: fused deposition modeling and semisolid extrusion [37]. In both approaches,
the preprinting material is extruded in a continuous stream through a nozzle. The nozzle or the
platform (or a combination of the two) is moved in the x, y, and z directions to produce the final
desired geometry.
Fused deposition modeling utilizes a heated extrusion nozzle. Filaments are fed through the
heated nozzle and then deposited onto the print bed containing the emerging part. As the filament
cools, the layers fuse together. Heat-based printer nozzles are essentially limited to thermoplastics,
as the material must decrease in solidity and viscosity as the temperature is increased, and then harden
and bond on the print bed [38]. For pharmaceutical applications, filaments are usually prepared
by incorporating active compounds via hot melt extrusion; however, recent advances include direct
powder extrusion, which circumvents this process, and may enable a larger number of printable
materials [39].
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Figure 1. Typical ad it ve manufacturing mechanisms. Additive manufacturing techniques are
classified by their depositi n of material in a l yer-by-layer fashion. Material extrusion (A) tradit ally
deposits thermoplastic materials, but also includes pneumatic and mechanical deposition of semisolid
materials. Both material jetting (B) and binder jetting (C) rely on familiar inkjet heads; in material
jetting the entire print material passes through the nozzle, while in binder jetting, only a binder is
deposited. An advantage of binder jetting is the support of the powder bed, negating the need for
support structures or sacrificial material. This mechanism is also seen in selective laser sintering
(D), where the powder bed is selectively fused by a laser. Finally, stereolithography (E) selectively
polymerizes a liquid resin vat, thereby producing the desired part.
Semisolid extrusion techniques extend extrusion printing to a wider range of temperatures
and materials, including living material (termed “bioprinting”) [40]. Instead of relying solely on
heat, semisolid extrusion printers can print a variety of materials using pneumatic or mechanical
extrusion forces. In these systems, the rheological properties of the fluid to be printed and the
method of solidification must be carefully considered. For steady extrusion, fluids must have the
correct viscosity. Non-Newtonian fluid behavior, such as shear rate dependence, is often a factor
that must be taken into account [41]. After extrusion, solidification can occur through physical or
chemical processes. For example, printers fitted with UV lamps can cross-link newly printed layers of
photolinked hydrogels. Alternatively, the crosslinking agent may be printed at the same time as the
print material [42]. These gelation processes are a key consideration in the design of materials to be
used in semisolid extrusion prints.
The motions in the x–y plane and z-axis are typically actuated with extreme precision—down to
1 micron. In terms of feature resolution, fused deposition modeling is essentially limited by the size of
the extrusion nozzle. Typical sizes of fused deposition nozzles are in the range of 400 microns [43–46].
Semisolid extrusion usually has relatively poor feature resolution, as lower-viscosity substances spread
upon printing [37].
Hybrid techniques can push the feature resolution of extrusion printing to the range of ten
microns [47]. In these printers, the extruded filament is subjected to an electric force, producing a much
smaller filament stream. These “electrospinning” hybrids are commercially available and represent the
highest resolution extrusion-based methods currently available [48,49].
Pharmaceutics 2019, 11, 390 4 of 22
2.2. Material Jetting
The mechanism of material jetting is similar to that of familiar inkjet printers. For 3D materials,
the print head and platform are actuated to move in the x-, y-, and z-axis. For successful printing,
the material must be cross-linkable upon delivery. As with semisolid extrusion, cross-linking processes
include photo, thermal, ionic, and pH-dependent effects [41]. One of the greatest advantages of
this technique is that it may be used to print multiple materials simultaneously, even materials with
different properties [50]. Material jetting is used for both small molecules and bioprinting [40,41].
The final feature resolution of material-jetted prints depends on the droplet size. Print feature
resolution is also highly dependent upon the rheological properties of the fluid and print speed, which
must be carefully parametrized. Upon arrival onto the print, droplets tend to spread before they are
fully cross-linked, which limits inkjet resolution. Additionally, the most defined features tend to be
printed in parallel to the inkjet direction [36]. Inkjet manufacturers advertise feature resolution in the
range of 20 to 100 microns [51].
2.3. Binder Jetting
While material extrusion and material jetting may be printed onto a variety of surfaces, binder
jetting requires the use of a powder which may be selectively bound by the addition of a liquid binder.
For the creation of each layer of the part, a layer of powder is spread across a printing surface [36].
An inkjet head then deposits binder in the desired geometry. The powder bed is then lowered, the new
powder is spread, and another layer is selectively bound. This technique can require high volumes of
powder, but has no need for sacrificial materials, as the powder bed can support the emerging part [52].
Advantages of this technique include the possibility of multimaterial printing, as multiple binding
agents may be used [36]. Additionally, this manufacturing process can often occur at room temperature,
and it easily makes porous structures [36]. Metals and ceramics are commonly used, but polymers may
also be printed [36]. Materials printed in this way require postprocessing, such as chemical treatment,
for better mechanical properties. Many printers have a feature resolution of two millimeters [36],
but better printers can produce up to 50-micron feature resolution [12], dependent on powder particle
size [36].
2.4. Selective Laser Sintering
Selective laser sintering occurs in a similar fashion to binder jetting, but instead of using a
binder to fuse powder particles, a laser is used to sinter them together. Because of this mechanism,
only materials that can be fused by laser are utilized. Metals and ceramics are common, although the
use of thermoplastics is increasingly prevalent, especially in biomedical applications [13,53–55]. For all
materials, careful calibration of the powder to be used is important, as particle size will affect feature
print resolution, workability of particle spreading, and final print mechanical properties [56,57].
The feature resolution of selective laser sintering depends highly on the material. While some report
feature resolutions in the range of 100 microns [12], selective laser sintering can be a high-resolution
technique, producing features as small as 30 microns [58]. As with binder jetting, parts are usually
porous and need postprocessing for smooth surfaces and mechanical strength. Additionally, selective
laser sintering is usually fast and economical, requiring no support materials. When printing metals or
ceramics, sterilization via an autoclave is a viable option.
2.5. Stereolithography
The oldest form of additive manufacturing, stereolithography, relies on the same techniques as its
predecessor, photolithography. Stereolithography is based on the reaction of light with photopolymer
resins. First, a large vat is filled with resin and subjected to a radiation source from the top or the
bottom, in a desired geometric pattern. The bottom-up method, which features lower resin volumes,
places the light source under the resin tank with a transparent base (as pictured in Figure 1) [37].
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The light-cured layer polymerizes, and the build platform moves upwards, peeling the cured layer off
the bottom surface. Another layer is then polymerized in a similar fashion. Alternatively, in top-down
stereolithography, the actuator platform is lowered for each layer, requiring larger volumes of material
for the part to remain fully immersed [59]. Continuous liquid interface processing (CLIP) and digital
light processing (DLP) are other techniques related to stereolithography [37]. Stereolithographic
techniques can offer relatively high resolution, by reaching the diffraction limit of light simply using
conventional radiation sources. Some print quality can suffer from nonspecific photopolymerization
due to light leakage [60]; however, the highest feature resolution is often reported as 20–30 microns in
commercially available printers [61–63].
The printing process often requires post-curing, postprocessing, and sacrificial support structures.
There is also a limited number of materials that may be used, but these include, prominently,
photocurable polymers [37]. Some metals and ceramics may be printed in specialized machines and
processes [64]. Recent studies have demonstrated the incorporation of active pharmaceuticals in the
resin to be effective [65,66].
With increased cost, increased feature resolution is possible with two-photon polymerization,
a specialized form of stereolithography. In two-photon polymerization, resins are polymerized using
two laser beams. These machines can exceed the diffraction limit and produce feature resolution of
120 nm [67,68].
2.6. Resolution
The preceding feature resolutions are given as a range based on manufacturer specifications and
literature (Figure 2 and Table 1). However, the reporting of resolution is non-standard across the
industry. Manufacturers report any of the following specifications; x–y resolution, layer thickness, part
accuracy, and nozzle size [43,69].
Typically, the layer thickness is the most straightforward specification to find, and values range as
low as 5 microns, depending on the type of printing being used [12]. This same value may, however,
be inaccurately reported as x–y resolution. Print x–y resolution is often a function of the material
printing method: material extrusion rarely can provide structures finer than the nozzle, powder
methods are limited by the powder size, and inkjet printers are limited by droplet size [12].
The smallest feature resolution, which is dependent on geometry, print speed, temperature,
and material, is of the uppermost relevance to the biomedical designer. However, the smallest feature
resolutions are not standardly reported. For example, material extrusion manufacturers commonly
report accuracy to 100 microns using a 400-micron nozzle, indicating a difference between accuracy
and smallest feature size [43,46]. Literature has attempted to address this [70,71], but more research in
the area would be invaluable.
Continued innovation will push the boundaries of the current resolution limits, but standard
printing techniques are within the range of critical biological entities [72]. All printer types can print
in the micro-scale, which is defined as printing of features smaller than 1000 microns. Additive
manufacturing brings unique capability to this field. While topography on a micro-scale can be created
relying solely on material properties, additive manufacturing allows engineering design of specific
micro geometries. As discussed in the following sections, printing on a micro-scale—within the range
of single cells and microvasculature—can produce unique solutions for drug discovery, development,
and delivery.
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Figure 2. Maximum feature resolution of various 3D printing techniques, as compared to typical 
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methods, such as two-photon polymerization (2PP) and electrospinning hybrid extrusion (ME + E) are
required for printing sizes comparable to single cells. Material extrusion (ME) feature resolution is
essentially limited by nozzle size, while material jetting (MJ) and binder jetting (BJ) feature resolution
is limited to droplet size. Binder jetting and selective laser sintering (SLS) feature resolution both
depend on particle powder size, while stereolithography (SLA) has superior feature resolution
based on the light source. However, for all print types, feature resolution depends highly on the
designed geometry and print orientation. Data was compiled from manufacturer technical specification
sheets [43–46,48,49,51,61–63,69,73–83] and literature [24,36,38,60,84,85]. Material extrusion values
extracted from specification sheets are based on nozzle diameter.
Table 1. Representative commercial printers with their associated feature resolutions and applications
in the literature. Feature resolution data is taken from manufacturer technical specification sheets.
Material extrusion values extracted from specification sheets are based on nozzle diameter. However,
the smallest feature size is dependent on geometry, print speed, temperature, and material, and is
not standardly reported. High-resolution printing techniques find applications in the printing of
oral dosages, microneedles, micro-swimmers, and micro-implants. Material extrusion is a popular
technique in the printing of oral dosages, whereas the feature resolution of stereolithography and
two-photon polymerization are necessary for use in microneedles and micro-swimmers.
3D-Printing Type Printer Resolution (µm) Applications
Electrospinning
Hybrid Extrusion
RegenHU Benchtop 3D
Discovery Evolution 5 [48] Oral Dosages [25,26]
GeSiM Bioscaffolder 3.2/4.2 10 [49] Micro-implants [29]
Material Extrusion
LulzBot TAZ 5 350 [75] Microneedles [24]
MakerBot Replicator 2,
ZMorph 2.0 SX 400 [43–45] Oral Dosages [30–35,86]
Solidoodle 2 Base 400 [46] Micro-implants [21]
Material Jetting 3D Systems Phenix PXM 20 [51] Micro-implants [14,15]
Binder Jetting Z Corporation Spectrum Z510 300 [79] Micro-implants [16]
Two-Photon
Polymerization
NanoScribe Photonic
Professional 0.15 [80]
Microneedles [22]
Micro-swimmers [19,20]
Stereolithography
Envisiontec Perfactory DSP III
Standard SXGA+, Kudo 3D
Titan 1, Carbon M2
25–75 [61,63,83] Microneedles [17,27,28]
3D Systems ProJet 6000 25 [62] Micro-swimmers [23]
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3. Controlled Release
Additive manufacturing is gaining traction for use in drug delivery, having applications in drug
delivery methods and devices [87–89]. Oral drug delivery devices, tablets, are one such application
of additive manufacturing in the medical field, Spritam® being the first FDA approved 3D-printed
medicine. The incorporation of micro-geometry has unique advantages in terms of controlled
release. Additive manufacturing can produce geometries that are impossible or impractical via typical
pharmaceutical manufacturing processes (Figure 3).
One of the most straightforward geometric modifications—infill percentage—relies on the intrinsic
material extrusion methods. Parts to be printed via material extrusion are commonly printed by first
depositing an outer shell and subsequently filling this shell with preset infill geometry; 0% infill would
leave the part fully hollow, while 100% infill creates a solid part. For use in oral drug delivery, Verstraete
et al. demonstrated that lower infill percentages have faster release profiles [90]. Immediate release
profiles are often desirable, as in pain relievers. Verstraete’s release profile results are due to the increase
of surface area to volume ratio for the prints. Importantly, Kyobula et al. likewise demonstrated that
this process is also dependent on wettability [91]. Spaces and cavities under the size of 600 microns
were less wettable, producing longer release times than counterparts with >600-micron cavities. Other
literature reports the correlation between infill, micro-geometry creation, and release profile [92,93].
Similarly, Li et al. showed that varied infill percentage could be tailored to create gastro-flotation
tablets [94]. Prolonged retention enhances the bioavailability, and lower infill percentages produce
floating without sacrificing mechanical properties such as friability.
Conventional tablet release profiles are dominated by various physical forces, of which surface
area to volume ratio plays a significant part. In these systems, drug release is often dominated by
diffusion patterns. One method for creating more complex release profiles is the incorporation of
outer layers, to produce, for example, enteric coatings which delay the release until the intestinal tract.
These controlled release tablets are achievable through additive manufacturing, as demonstrated by
Okwuosa et al., who showed that an outer coating of ≥520 microns was necessary to produce the
intended release profile [95]. The feature resolution of the printer was also shown to affect the release
profile, where low-resolution printing resulted in coating layers thicker than the nominal dimension.
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Figure 3. Idealized release profiles (left) and micro-geometry incorporation in oral dosages produced
by additive manufacturing techniques (A–F). Immediate release is desirable for quick action drugs,
such as pain relievers. Immediate release profiles are correlated to infill percentage (A) [91], and
other factors such as wettability. Infill percentage may also be exploited for gastro-floating devices
(B) [94]. If combined with a shell of variable thickness (C) [96], infill variation can also achieve tunable
zero-order release. More complicated geometries offer release profiles that are dependent on erosion,
providing immediate release profiles (D,E) [34,55]. Additionally, pulsatile release is possible with the
fabrication of an outer shell of tunable thickness, here designed to be 600 microns (F) [33]. Reproduced
with permission from Elsevier (A–F).
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For multilayer tablets, Zhang et al. demonstrated that release mechanisms are dependent on several
parameters, including both infill percentage and shell thickness [96]. By varying these parameters,
release profiles could be dominated by diffusion or swelling (or a combination), and the authors were
capable of tuning until a zero-order release was achieved. Other literature similarly reports zero-order
(or constant sustained) release [97,98]. These applications demonstrate the importance of small features
in CAD designs for drug delivery. Micro-geometry and feature resolution have also been shown to be
important in orodispersible, thin-layer films [99,100].
Other, less familiar shapes are also possible with additive manufacturing [35,101]. Whereas varied
infill produces pores that are initially separated from the aqueous media, several groups have made
channels and holes that cross the entire tablet. These channels were demonstrated by both Sadia et al.
and Arafat et al. to produce much faster release profiles, putting them within the pharmacopeial
regulations for immediate release [30,34]. These release profiles were a function of geometry; features
in the range of 1000 microns seem optimal. Erosion becomes a dominant force in the dissolution of
these tablets, as the tablet breaks into pieces as time progresses. Likewise, Fina et al. found faster
dissolution for their gyroid structures, which could be paired with nonporous regions for complex
release profiles [55].
Many of the presented examples rely on specific pairings of active pharmaceutical and polymer,
which are then extruded through hot-melt extrusion [30,33,35,86,90,96,102]. The properties (rheology
for material jetting, thermoplasticity for material extrusion, and particle size for binder jetting) must be
carefully tuned and parameterized for each drug. Typically, active pharmaceutical is incorporated
into filament at a rate of 4–8% w/w [31,35,55,91,94]. Some attempts have been made to create fully
flexible systems. For example, Melocchi et al. have demonstrated a pulsatile release profile based on
material extrusion of a shell (thickness 600 microns) which could be used for any number of active
pharmaceuticals [33].
4. Minimally Invasive Delivery
Hypodermal needles are common for drug delivery in which oral ingestion is inappropriate;
the method, however, is invasive. Additive manufacturing provides alternative solutions for minimally
invasive delivery through the design of microneedle arrays.
The first transdermal drug delivery system was introduced in 1979, and since these systems
have become more sophisticated with the addition of microneedle arrays [103]. Microneedle arrays,
as compared to hypodermal needles, improve patient compliance, decrease pain and tissue damage,
decrease the need for skilled healthcare professionals for administration, and inhibit microbial
entrance [104,105]. Additionally, transdermally delivered drugs can elicit a higher immunogenic
response and increased bioavailability.
The efficacy of such systems is highly dependent on geometric properties. As Johnson et al. note,
key parameters in the design of microneedle arrays include microneedle shape (height and diameter)
aspect ratio, composition, strength, sharpness, spacing, and quantity [28]. For example, a decrease in
aspect ratio corresponds to an increase in microneedle mechanical strength [106], whereas material
composition and toughness facilitate penetration deepness [28]. Needle spacing is directly related
to how much force is necessary for penetration [107]. Dimensions are variable, depending on the
application. As Lu et al. note, various microneedle heights ranging from 150 to 2000 microns have been
reported [103]. The microneedle array must at least penetrate the stratum corneum layer, the outermost
layer of the skin, which is in the range of 10 to 20 microns [108]. To draw blood, the microneedle height
must be at least 900 microns [109]. Optimal tip size is a function of material—robust materials have
improved penetration at small tip sizes, while polymers at the same dimensions easily fracture [106].
The possibility of creating these structures via additive manufacturing is, therefore, limited by the
feature resolution of the technology. Stereolithography (including two-photon polymerization) is the
additive manufacturing technique most widely used for this purpose [22,27,28,104,109–115].
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Different shapes are possible, each tailored for various applications (Figure 4). Pere et al.
demonstrated that between cones and pyramids, cones took less force to penetrate, perhaps due to the
decrease in microneedle-to-skin contact area [104]. Solid microneedles such as these are coated with
active pharmaceutical ingredients, which are then deposited upon application. These systems must be
carefully tuned for full biocompatibility and resistance to fracture. Another approach is to puncture
the skin using solid microneedle arrays, and then apply drug topically, improving topical access via
the punctures. Daraiswamy and Gittard developed various hollow microneedles with complex hollow
geometry [111,115]. After puncture, an active pharmaceutical may be added, facilitating delivery.
Alternatively, active pharmaceuticals may be incorporated with the needles and applied simultaneously.
Needles are removed after application.
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Fully di s lvable m croneedle arrays are a viable strategy for prolonged release. These arrays are
typically made through polymer molding, which is not an additive manufacturing technique [116].
Limited print material capability in stereolithography and resolution limits in other methods
challenge additive manufacturing for needles of this kind. As innovative materials are developed for
stereolithography, and high-resolution versions of other printing types become available, this strategy
may be realized. Currently, inkjet printing for coatings of microneedle arrays has received attention as
a high-resolution, highly flexible method [104,105,116–120].
Luzuriaga et al. showed an innovative approach to the fabrication of microneedles, extending
the technology to material extrusion [24]. However, as expected, the feature resolution of the printer
resulted in the impossibility of creating sharp peaks. The smallest producible tip diameter was more
than twice the optimal size, so postprocessing in basic solution was necessary to produce viable
microneedles. This speaks to why stereolithographic techniques dominate these applications. It should
be noted, however, that standard resolution stereolithographic printing reports distortion in final print
features, compared to the CAD model [27]. Despite challenges, additive manufacturing of microneedle
arrays can streamline prototyping and enable the fabrication of complex geometries [28].
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5. High-Precision Targeting
Some drug delivery applications require high-precision targeting, as do cancer treatments [7].
Highly specific delivery aims to provide a higher dose to a localized area while simultaneously reducing
systemic toxicity. This delivery is often intended for parts of the body that are hard-to-reach and
confined, thus making them difficult to approach through conventional methods. Thus, two lines
of innovation—micro-swimmer devices and micro-implants—are fabricated to provide solutions
(Figure 5).Pharmaceutics 2019, 11, x FOR PEER REVIEW 10 of 22 
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micro-swimmers mechanically pick up the cargo (B) [122]. Wit high-resolution pri ting, complex
micromachine structures can be fabricated, incl ing caps les and syringes (C) [18]. Micro-implants
can offer long term release profiles, based on drug incorporation within the scaffold in material extrusion
(D) [123]. The dual-pulsed release is also possible, via geometric patterning in binder jetting (E) [124].
Scale bars: 20 µm (A,C) and 10 µm (B). (A) Reproduced with permission from American Chemical
Society (A), Wiley (B,C), and Elsevier (D).
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5.1. Micro-Swimmer Devices
Micro-swimmers are motile delivery devices currently under developmental research.
These devices are reviewed elsewhere [125,126]; the basic principles are summarized here to highlight
the incorporation of additive manufacturing into the field. Micro-swimmer devices function on a
variety of mechanisms, but all have essentially three stages: loading, transportation, and release.
Micro-scale geometry can contribute significantly to each stage.
Loading can be achieved through passive adsorption [19,127], surface chemistry, incorporation of
pharmaceuticals in the print material [23], or mechanical trapping within arms or syringes [18,122].
In the case of arms, the micro-swimmer needs to be maneuvered carefully to entrap the particle
in a ring of extending rods (Figure 5B) [122]. In the case of syringes, Huang et al. designed
micro-swimmers with Archimedean screw pumps, which were magnetically actuated (Figure 5C) [18].
By alternating the magnetic field, the pump could be selectively turned one way or another, producing
fluid vortices sufficient for particle trapping. These latter approaches are complex and not fully
efficient—incorporation of the desired particles within the object material may prove to be the superior
method. These latter means are, however, fully dependent on geometry.
Transportation mechanisms are then engineering for motion to the target tissue. Actuation
methods may be based on magnetic, thermal, chemical, electrostatic, or mechanical stimuli [18]. Upon
excitation by one of these stimuli, micro-swimmers will move in the desired direction, depending
on their shape, working their way through in vivo vascular systems. Of these methods, magnetic
actuation is prominent, as magnetic fields are noninvasive and body tissue may be considered
essentially nonmagnetic. Micro-swimmer devices using this mechanism are either plated with
magnetic material [18,127] or have magnetic material incorporated [23,121], so the devices will respond
to a magnetic gradient or a rotating magnetic field. A rotating magnetic field is preferable for its
increased strength [23].
At the micro-scale, viscous forces dominate inertial forces, especially for small devices in body
fluid, a non-Newtonian fluid [128]. Thus, the geometry must be carefully constructed for motion
on this scale. Natural solutions to this problem include flagella and cilia, and these solutions have
inspired many of the current micro-swimmer devices [20]. A typical shape is a cylinder encased
by a helix or double helix. Ceylan et al. remark that double helices are more stable than a single
helix, and carefully parameterized their helix to produce optimal swimming velocity [20]. Size is
also important, as micro-swimmers are meant to maneuver easily within the target tissue. However,
as Hunter et al. demonstrate, there is a trade-off between smaller size and higher possible velocity [23].
Typical helical structures have a length of 20 microns with a diameter of 5 microns. Other approaches
to transport are not dependent on helical geometry, but instead on the incorporation of motile sperm
cells [19]. Because these devices are currently in research development, testing of motion in vivo is
limited. Similarly, testing in low-Reynolds regime fluids that accurately model body fluids is not
consistent in all literature, a challenge which will need to be addressed for the application of these
devices in pharmaceutical administration.
Release mechanisms vary and may be dependent on simple diffusion [23], light [121], magnetic
fields [18], or mechanical stimuli [19]. Even structurally similar systems can be highly variable.
One hydrogel system demonstrated enzymatic degradation to release the payload [20], whereas another
used light as a trigger for tunable release [121]. Akin to oral dosages, release profiles are affected by
erosion and swelling processes for hydrogel micro-swimmers or diffusion for non-hydrogel systems.
For these applications, high feature resolution is necessary. Thus two-photon polymerization
is almost exclusively used. Two-photon polymerization is a cutting-edge technique for prototyping
these devices: no other manufacturing methods parallel in shear flexibility. However, two-photon
polymerization is essentially limited to photopolymers. Incorporation of particles (such as
pharmaceuticals or magnets) in the resin is one strategy to achieve a wider variety of functional
materials. Micromolding from 3D-printed molds has also been demonstrated [23], boasting a wider
variety of possible materials.
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5.2. Micro-Implants
Non-mobile drug delivery devices can also provide high-precision targeting and release.
These drug delivery methods, termed micro-implants, can provide long-lasting release profiles,
regenerative tissue effects, and restoration of tissue function. Implants are a long-standing part of
conventional medicine; the use of additive manufacturing in implants is similarly well established [129].
Design considerations are important for both drug-eluting and inert implants. As shown here, additive
manufacturing can enable solutions for both.
Microstructure is a key feature of implanted materials as it governs interactions with resident
cells [130]. Optimal pore size, for example, is dependent on tissue type. Bone implants are made
with pores in the range of 200 to 400 microns [131–133]. Pore size plays a role in differentiation, cell
perfusion, and nutrient exchange, and stands as an example of important micro-geometry.
Additive manufacturing has the unique capability of fabricating macrostructure and
micro-geometry simultaneously. Most additive manufacturing techniques have been applied to
making implant materials and tissue scaffolds, including material extrusion (both fused deposition
modeling [21] and semisolid extrusion [29,134]), binder jetting [131,135], and selective laser sintering [14].
Because the microstructured design for many scaffolds is above 200 microns, the design of biomimetic
pores is within the resolution range of most printers.
Ideal bone implant materials should be biodegradable, osteoconductive, osteoinductive,
angiogenic, and resistant to bacteria [132]. The incorporation and controlled release of compounds into
the scaffold can help create these properties. Research has shown the incorporation of growth factors
(esp. recombinant human bone morphogenetic proteins (rhBMP) or vascular endothelial growth factor
(VGEF)) to enhance proliferation and bone response [29,134,136]. Antibiotics may also be feasibly
incorporated [16,135].
Besides merely augmenting the properties of the scaffold, controlled release can provide
pharmaceutical solutions (Figure 5). For example, in tuberculosis treatment, Zhu et al. and Wu et al.
have demonstrated the incorporation of multiple drugs to provide programmed release [123,124].
While Zhu et al. showed prolonged release from a scaffold printing via material extrusion, Wu et al.
designed dual-pulsed release by incorporating multiple layers of different drugs, manufacturing
via binder jetting. In cancer treatment, Maher et al. showed biphasic release from their implant
material [14]. This release is highly specific—providing stronger therapeutic effects and, importantly,
lower systemic toxicity. While micro-swimmers must be guided to the target tissue, micro-implants
are surgically placed in the area needing the most pharmaceutical treatment.
In these systems, the spatial distribution of the drug layers is a determining factor in the release
profile, as was seen in oral dosages. For example, Martinez-Vazquez et al. showed first order
kinetics due to their design [137]. Often, however, drug release profiles from scaffolds are biphasic:
a quick release burst followed by prolonged release [14,131,134]. Prolonged release may be as long
as 80 days [123]. Thus, there are clear benefits to the incorporation of additive manufacturing and
pharmaceuticals into implants.
6. Biomimetic Models for Drug Discovery and Development
Whereas the preceding examples have all dealt with drug delivery, additive manufacturing can
also be employed in the drug discovery and drug development phases. Perhaps the most viable
application of additive manufacturing in drug development is the creation of organ models.
In manufacturing organ models, numerous techniques are currently employed. Monolayer cultures
are an industry standard, due to their ease and reproducibility, despite the fact that the response of
cells in such cultures is often different than in three-dimensional counterparts [138]. No methods
have been able to produce fully biomimetic structures with the resolution and three-dimensional
architecture found in vivo. However, fully functional organ models have the potential to provide
better translational data towards clinical trials [6]. They also have a capacity to limit the cost later in
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the drug development process, excluding compounds earlier and increasing the accuracy of testing.
This provides a strong impetus for development in this industry.
Additive manufacturing for use in drug development has been extensively reviewed
elsewhere [139]. Thus, we focus on demonstrating how micro-scale geometry is a key consideration in
the design of organ models and functional tissue (Figure 6).
Vascularization in vivo is a prime example of the importance of micro-scale geometry.
Microvasculature is composed of arterioles, capillaries, and venules, which form a complex
network [140]. In this network, lumen diameters range between 5 and 200 µm for capillaries
and arterioles, respectively [140]. Without vascularization, the nutrient exchange is weak, and necrosis
occurs. Much research, therefore, has sought to create vascularization, the realization of which would
provide more fully biomimetic structures [141]. For pharmaceutical development, the incorporation of
vasculature helps promote realistic cell viability and drug response [142,143].
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Various strategies exist in the creation of microvasculature; additive manufacturing brings unique
approaches. Printing methods include the incorporation of sacrificial materials, designed spaces,
or even direct printing of endothelial cells (Figure 6A–E) [140]. Scaffolds printed with sacrificial
materials or designed spaces are typically seeded after printing and postprocessing, while bioprinting
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is capable of placing cells throughout the scaffold. The defining feature of these systems is a need for
simultaneous design of macro and micro features, which additive manufacturing is uniquely suited
to create. However, capillary-sized features are beyond the current printer feature resolution for the
majority of extrusion printing, the most common type of bioprinting [139]. Advances in the feature
resolution for additive manufacturing are of importance for this aim.
Various tissues are the focus for bioprinting, including skin, liver, bone, cartilage, cardiac,
and adipose tissue [6]. Of these, the liver is most important to pharmaceutical drug development,
as many drugs fail clinical trials due to the detection of toxicity to the liver. Liver function depends on
its microenvironment [5]. In vivo, functional liver tissue is made of both hepatocytes and supporting
endodermal and mesodermal cells [144,145]. With this in mind, Ma et al. designed a bioprinted
organ slice, which depends on the micron resolution placement of hepatic and supporting cells
(Figure 6F–H) [144]. As in the case of vasculature, designs of this complexity are made possible
through high-resolution additive manufacturing techniques. Multimaterial printing methods bring an
increased spatial control unseen with other manufacturing methods [142].
Other cells that might be used in drug discovery display responses to micro-scale geometry:
cardiomyocytes display alignment based on feature widths [146], and have been patterned in a
filamentous matrix for drug discovery based on these effects [147]. As discussed previously, pore size
plays a role in cell differentiation for bone cells and adipose-derived mesenchymal stem cells [148].
Thus, cell response to the engineered environment should be carefully tailored to produce the intended
cell morphology and differentiation. Micro-scale, cell-size features are a key design parameter. The goal
of these engineering systems is to provide the optimal cell response for use in drug development,
allowing for data with better translational and predictive qualities. Besides the use of bioprinted
scaffolds for application in drug discovery and organ-on-a-chip and microfluidic devices are also
emerging as alternatives that may be created via additive manufacturing [149].
7. Future Challenges and Opportunities
The future is bright for the use of additive manufacturing in the pharmaceutical field; however,
this future is not without obstacles. Traditional methods are more suited for mass-production than is
additive manufacturing. Whereas injection molding becomes more cost-effective as the production
rate rises, additive manufacturing of prints remains constant in cost per part [150]. While additive
manufacturing significantly reduces prototyping time, it takes more time per part than traditional
methods such as injection molding [52]. Increasing print speed is challenging, as there is generally a
trade-off between feature resolution and print speed [60]. Higher feature resolution printing methods,
such as stereolithography, selective laser sintering, or electrospinning hybrid extrusion have increased
the cost for materials and a higher amount of energy necessary for processing [52]. Thus, additive
manufacturing is historically well suited for rapid prototyping and design of devices, but not mass
production. However, the features discussed previously are dependent on geometry only possible with
additive manufacturing. Therefore, the development of additive manufacturing for mass-production
is of great interest to the pharmaceutical industry.
Material science will continue to be a key field for additive manufacturing development. While
the selection of materials for printing has grown exponentially in the last decade [41,151], materials
specifications will continue to limit and inform the feasibility of additive manufacturing processes
for specific applications. In consideration of materials, bioprinting of extracellular matrix material
is poised for high impact in the field of 3D bioprinted scaffolds [152]. Improvements in material
possibilities and printing methods may facilitate larger-scale solutions.
While this article has mainly focused on resolution, other important material properties include
printability, mechanical properties, and drug loading capacity [41,153]. For example, bone implants
should mimic in vivo bone stiffness, and research on micro-implants characterizes mechanical properties
such as Young’s modulus [21], compressive strength [29], and yield stress [15]. These properties are
dependent on printing method, geometry, and drug loading content. Mechanical properties are also
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important in oral dosages; as previously stated, microstructured oral dosages can be carefully designed
for zero friability [30]. High-resolution printing is complex and requires geometric design, material
selection, and printing parametrization to achieve biomedical solutions.
These technologies are making personalized medicine more feasible, as the customizability
of additive manufacturing remains the most apparent benefit. The time necessary to print to
identical shapes is comparable to the time necessary to print to customized shapes. Additive
manufacturing already has a widespread application in the dental industry, where patient-specific
parts are necessary [154]. In a similar way, patient-specific therapy remains a promising application
of additive manufacturing in the pharmaceutical industry. Point-of-care fabrication of tailored
medications is becoming increasingly possible [155]. Orphan medications, which cannot profitably
be manufactured at a large scale, could be produced on an individual, small-batch level to reach the
needs of patients [156]. Additive manufacturing is uniquely suited for this application.
In the case of oral drug delivery, various authors have addressed the printing of tablets with fully
customizable release profiles [157]. As presented, these release profiles are tuned by infill percentage
or geometric structure. For example, dose combination or “polypills” are an emerging possibility
afforded by additive manufacturing [86]. Maroni et al. demonstrated a shelled capsule capable of
dual-pulse controlled release [32]. Their design took advantage of wall thickness and polymer selection
for the timing of release. Khaled et al. showed both a three-in-one combination and a five-in-one
combination based on spatial separation of active ingredients [25,26]. For each of the preceding cases,
the microstructure is a key feature enabled by additive manufacturing.
Larger features are also personalized. Lim et al. designed a finger splint which could be
3D-printed in tandem with microneedles for drug delivery [27]. The design hoped to optimize
skin-to-microneedle contact, thereby increasing efficiency, being made specifically for the user’s hand.
Drug releasing implants made via additive manufacturing also show macrostructure easily tailored
to each patient [123]. Printed pediatric stints have already been shown to be effective personalized
medical implants in hospital settings [158]. High-resolution printing, therefore, augments current
efforts towards personalized medicine. These tablets could be designed, fabricated, and distributed on
a case-by-case basis, the entire process occurring at the local clinic.
Regulation of these applications will likely prove to be one of the most challenging hurdles before
the wide-spread application of this technology [159]. However, the implementation of microstructured
devices made via additive manufacturing promises to shift the paradigm of the industry and enable
solutions to the challenging and nuanced problems currently faced.
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